請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24698
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄧哲明 | |
dc.contributor.author | Yu-Chun Huang | en |
dc.contributor.author | 黃煜珺 | zh_TW |
dc.date.accessioned | 2021-06-08T05:37:16Z | - |
dc.date.copyright | 2005-01-19 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-01-17 | |
dc.identifier.citation | 參考文獻
Allman R, Errington RJ, Smith PJ. Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress. Br J Cancer 88: 1649-58; 2003. Afford SC, Pongracz J, Stockley RA, Crocker J, Burnett D. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils. J Biol Chem 267:21612-6; 1992. Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 91:1700-5; 1998. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by proteaseme. Cell Growth Diff 11:355-60; 2000. Bader T, Yamada Y, Ankel H. Antiviral activity of the prostanoid clavulone II against vesicular stomatitis virus. Antiviral Res 16:341-55; 1991. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265:17141-9; 1990. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148-58; 1995. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 84:623-31; 1996. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 101:2940-54; 2003. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-86; 2003. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PI, Neckers L, Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57:130-5; 1997. Blagosklonny MV. Unwinding the loop of Bcl-2 phosphorylation. Leukemia 15:869-74; 2001. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 72:743-81; 2003. Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157-68; 2003. Castedo M, Perfettini J-L, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-37; 2004. Caudron N, Valiron O, Usson Y, Valiron P, Job D. A reassessment of the factors affecting microtubule assembly and disassembly in vitro. J Mol Biol 297: 211-20; 2000. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, Santoli D. The severe combined immuneodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene 7:827-36; 1992. Chen HY, Shiao MS, Huang YL, Shen CC, Lin YL, Kuo YH, Chen CC. Antioxidant principles from Ephemerantha Ionchophylla. J Nat Prod 62:1225-7; 1999. Chiou WF, Chen CF. Pharmacological profile of evodiamine in isolated rabbit corpus cavernosum. Eur J Pharmacol 446:151-9; 2002. Chiou, WF, Chou, CJ, Shum, AYC, Chen, CF. The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action. Eur J Pharmacol 215:277-83; 1992. Chiou, WF, Liao, JF, Chen, CF. Comparative study on the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J Nat Prod 59: 374-78; 1996. Cory S, Huang DCS, Adams JM. The Bcl-2 family: role in cell survival and oncogenesis. Oncogene 22:8590-607; 2003. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA 80:2926-30; 1983. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 96:3343-56; 2000. Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, Kornbluth S. Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol 24:10289-99; 2004. Dimberg A, Öberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines. Leuk Lymphma 44:1641-50; 2003. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido[2,3-d]pyimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60:3127-31; 2000. Dou QP, Mcguire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 289: 781-90; 1999. Duraj J, Sedlak J, Bies J, Chovancova J, Chorvath B. PSC 833 modulation of multidrug resistance to paclitaxel in cultured human ovarian carcinoma cells leads to apoptosis. Anticancer Res 22:3425-8; 2002. Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 110:780-90; 2000. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 411:342-8; 2001. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA, Chambers TC. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275:29980-5; 2000. Fei XF, Wang BX, Li TJ, Tashiro S, Minami M, Xing de J, Ikejima T. Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94:92-8; 2003. Fukushima M, Kato T, Narumiya S, Mizushima Y, Sasaki H, Terashima Y, Nishiyama Y, Santoro MG. Prostaglandin A and J: antitumor and antiviral prostaglandins. Adv Prostaglandin Thromboxane Leukot Res 19:415-8; 1989. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875-90; 2001. Ghaffari S, Wu H, Gerlach M, Han Y, Lodish HF, Daley GQ. BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. Proc Natl Acad Sci 96: 13186-90; 1999. Glover DM. Aurora A on the mitotic spindle is activated by the way it holds its partner. Mol Cell 12:797-9; 2003. Goldman JM, Melo JV. Chronic myeloid leukemia – advances in biology and new approaches to treatment. New Engl J Med 349:1451-64; 2003. Gorospe M, Liu Y, Xu Q, Chrest FJ, Holbrook NJ. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 16:762-70; 1996. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507-11; 1995. Hengartner MO. The biochemistry of apoptosiss. Nature 407:770-6; 2000. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 67:425-79; 1998. Honda A, Hong S, Yamada Y, Mori Y. Effect of marine coral prostanoids, clavulones, on spontaneous beating rate of cultured myocardial cells from fetal mouse hearts. Res Commun Chem Pathol Pharmacol 72:363-6; 1991. Honda A, Mori Y, Iguchi K, Yamada Y. Antiproliferative and cytotoxic effects of newly discovered halogenated coral prostanoids from the Japaness stolonifer Clavularia viridis on human myeloid leukemia cells in culture. Mol Pharmacol 32:530-5; 1987. Honda A, Yamamoto Y, Mori Y, Yamada Y, Kikuchi H. Antileukemic effect of coral-prostanoids clavulones from the stolonifer Clavularia viridis on human myeloid leukemia (HL-60) cells. Biochem Biophys Res Commun 130:515-23; 1985. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 114:909-16; 2001. Inoue S, Salmon ED. Force generation by microtubule assembly/disassembly in mitosis and related movements. Mol Biol Cell 6:1619-40, 1995. Ireland CM, Pittman SM. Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs. Biochem Pharmacol 49:1491-9; 1995. Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, Hofman P, Auberger P. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J 17:2160-2; 2003. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-64; 2002. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212-22; 1991. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10:123-30; 1998. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Rev Cancer 4: 253-65; 2004. Kato T, Fukushima M, Kurozumi S, Noyori R. Antitumor activity of | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24698 | - |
dc.description.abstract | 多種抗癌藥物是源自於天然物成分或是天然物經過化學結構上的修飾而得,然後廣泛的使用在癌症的治療上。在本篇論文中,我們針對數種天然物和化學合成物進行作用機轉的探討,這其中包括萃取自傳統中草藥石斛(Dendrobium nobile)分離出的成分denbinobin及吳茱萸(Evodia rutaecarpa)的成分evodiamine,還有來自海洋生物珊瑚(Clavularia viridis)的clavulone II,這些成分過去曾被報導指出具有抑制癌細胞生長的效果,而TW01是個新合成的化合物,惟這些成分確切的作用機轉都並不清楚,因此促成了我們在人類白血病細胞上的研究。
第一部份,我們探究denbinobin對人類慢性骨髓性白血病K562細胞生長分化的影響。在24小時的作用下,denbinobin會隨著作用濃度的增加,抑制細胞的生長,其IC50濃度約為1.84 | zh_TW |
dc.description.abstract | Natural products have long been an abundant source of therapeutic drugs and even today the natural products-derived anticancer compounds still contribute a lot to cancer chemotherapy. However, with a persistent increase of patients to cancer insults, there is a continuing need for development of new anticancer drugs. In the present dissertation, we examined the anticancer effects and elucidated the action mechanisms of several compounds in several human acute and chronic leukemia cells.
Denbinobin (5-hydroxy-3,7-dimethoxy-1,4-phenanthraquinone) has been reported to exhibit anti-tumor and anti-inflammatory activity. We evaluated the anticancer activity of denbinobin in human myelogenous K562 leukemia cells. Denbinobin inhibited cell viability with an IC50 value of 1.84 | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:37:16Z (GMT). No. of bitstreams: 1 ntu-94-D88443003-1.pdf: 3215626 bytes, checksum: ce997e1d9d16a157d0db0141e9d3bb60 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 目錄
縮寫表…………………………………………………………i 中文摘要………………………………………………………ii 英文摘要………………………………………………………v 第一章 緒論 背景與研究動機………………………………………1 白血病…………………………………………………3 細胞週期………………………………………………8 細胞凋亡………………………………………………10 微小管作用劑…………………………………………13 第二章 Denbinobin的抗癌作用探討—tubulin聚合化的角色與Bcr-Abl的調控機制 序言……………………………………………………20 實驗材料與方法………………………………………21 實驗結果………………………………………………27 討論……………………………………………………30 第三章 Evodiamine在人類T-淋巴芽白血病細胞誘發mitotic arrest及細胞凋亡作用 序言………………………………………………………46 實驗材料與方法…………………………………………47 實驗結果…………………………………………………49 討論………………………………………………………52 第四章 Cyclopentenone類前列腺素衍生物, Clavulone II, 引發人類前骨髓性白血病細胞凋亡的機制 序言………………………………………………………66 實驗材料與方法…………………………………………67 實驗結果…………………………………………………68 討論………………………………………………………71 第五章 TW01之抗白血病作用探討 序言………………………………………………………85 實驗材料與方法…………………………………………85 實驗結果…………………………………………………88 討論………………………………………………………92 第六章 結論與展望……………………………………110 參考文獻…………………………………………………115 | |
dc.language.iso | zh-TW | |
dc.title | Denbinobin等化合物之抗血癌機轉探討 | zh_TW |
dc.title | Mechanisms of anticancer action on human leukemia cells by denbinobin, evodiamine, clavulone II and TW01 | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 顏茂雄,楊春茂,林建煌,黃德富 | |
dc.subject.keyword | 白血病,血癌, | zh_TW |
dc.subject.keyword | clavulone II,denbinobin,leukemia,evodiamine, | en |
dc.relation.page | 124 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2005-01-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 3.14 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。